Inhibrx Biosciences, Inc. INBX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$130.19M+7.0% | -$140.06M-30.6% | -$107.22M+7.4% | -$115.83M-107% | $1.77B+2.0% | ||
| $2.35M-5.6% | $2.48M-4.8% | $2.61M-6.4% | $2.79M+7.2% | $2.6M+13.8% | ||
| $11.34M+1.8% | $11.14M-2.1% | $11.38M+1.9% | $11.17M-79.5% | $54.57M-6.7% | ||
| $2.64M+8.2% | $2.44M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$15K-108% | ||
| -$130K+96.1% | -$3.3M— | —— | —— | —— | ||
| -$17.43M-300% | -$4.36M-49.0% | -$2.93M-163% | $4.62M-85.0% | $30.73M-14.4% | ||
| $28K— | $0-100% | $119K+22.7% | $97K-95.7% | $2.25M-39.2% | ||
| -$1.97M-23.7% | -$1.6M-41.2% | -$1.13M-19.7% | -$944K+12.9% | -$1.08M+23.0% | ||
| -$28K-40.0% | -$20K-104% | $543K+345% | -$222K+80.8% | -$1.16M-105% | ||
| -$131.93M-1.6% | -$129.79M+9.5% | -$143.39M-2.5% | -$139.85M+16.4% | -$167.25M+14.0% | ||
| —— | —— | —— | —— | $1.5M-42.3% | ||
| —— | —— | —— | —— | -$1.5M+42.3% | ||
| $2.08M+29.3% | $1.61M— | —— | —— | —— | ||
| $77.07M-24.0% | $101.45M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$35.96M+71.3% | ||
| $10.38M+16.6% | $8.9M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.64M+8.2% | $2.44M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$1.97M-23.7% | -$1.6M-41.2% | -$1.13M-19.7% | -$944K+12.9% | -$1.08M+23.0% | ||
| -$28K-40.0% | -$20K-104% | $543K+345% | -$222K+80.8% | -$1.16M-105% | ||
| $393K+128% | -$1.4M+60.9% | -$3.58M+51.5% | -$7.38M-21.5% | -$6.07M-104% | ||
| —— | $1.8M-1.3% | $1.83M-1.3% | $1.85M-1.3% | $1.87M-1.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $499.7M-50.0% | $999.4M-33.3% | $1.5B-25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $125K+33.3% | $93.75K+50.0% | $62.5K+100% | $31.25K— | ||
| -$1.97M-23.7% | -$1.6M-41.2% | -$1.13M-19.7% | -$944K+12.9% | -$1.08M+23.0% | ||
| —— | $1.72M+33.3% | $1.29M+50.0% | $860K+100% | $430K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $99.97M— | ||
| —— | $0-100% | $6.3M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$131.94M-1.6% | -$129.83M+9.5% | -$143.44M-2.4% | -$140.13M+17.0% | -$168.75M+14.3% | ||
| -$131.94M-1.6% | -$129.83M+9.5% | -$143.44M-2.4% | -$140.13M+17.0% | -$168.75M+14.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Inhibrx Biosciences, Inc. generate?
- Inhibrx Biosciences, Inc. (INBX) generated -$131.9M in operating cash flow over the trailing twelve months.
- What is Inhibrx Biosciences, Inc.'s free cash flow?
- After $47.0K of capital expenditures, Inhibrx Biosciences, Inc.'s free cash flow was -$131.9M over the trailing twelve months, up 21.8% year over year.
- Where does Inhibrx Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
